Novel, Linkable TGF-b Inhibitor Payload Selectively & Safely Blocks Fibrotic Disease & Immune Suppression in Cancer Patients
- Developed first in class non-cytotoxic, linkable TGF-b inhibitor payload to selectively and safely block TGF-b, in an Antibody drug conjugate format
- SYN101 is a first in class immune cell targeted TGF-b therapy that restores immune function in cancer patients
- SYN303 is a myofibroblast targeted TGF-b therapy that blocks fibrosis and inflammation in a wide variety of fibrotic diseases